New data from the MOMENTUM 3 study showed for the first time that a heart pump can extend survival to five years and beyond for advanced heart failure patients Prior data1 have shown survival for advanced heart failure patients who […]
Tag: HeartMate 3
Abbott Confirms Capacity to Support Expanded Use of HeartMate 3™ Heart Pump
– Abbott has the capacity and supply to support increased demand for mechanical circulatory support (MCS) devices following Medtronic’s decision to stop the global distribution and sale of the Medtronic HeartWare™ ventricular assist device (HVAD) – Access to MCS devices […]
FDA Approves Labeling Update for Abbott’s HeartMate 3 Heart Pump for use in Pediatric Patients
– Abbott’s HeartMate 3™ heart pump approved for use for pediatric patients battling advanced heart failure – This life-saving technology provides new treatment option for underserved population ABBOTT PARK, Ill., Dec. 17, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced the U.S. Food […]
HeartMate 3 heart pump reduces burden of bleeding and stroke rates, eliminates pump thrombosis
Orlando, Fla., April 04, 2019 (GLOBE NEWSWIRE) — Patients with a newer version of a common heart pump experienced a reduced aggregate burden of bleeding and stroke rates – and no pump thrombosis requiring surgical exchange, compared to patients with […]
New Data for Abbott’s HeartMate 3™ Highlights Unparalleled Performance of Industry’s Leading Heart Pump
NEW ORLEANS, March 17, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced new late-breaking data from the MOMENTUM 3 study, the world’s largest randomized controlled trial to assess outcomes in patients receiving a heart pump to treat advanced heart failure. In reviewing data across the […]
ABBOTT’S HEARTMATE 3 HEART PUMP NOW FDA APPROVED FOR ADVANCED HEART FAILURE PATIENTS NOT ELIGIBLE FOR A HEART TRANSPLANT
ABBOTT PARK, Ill., Oct. 19, 2018 /PRNewswire/ — Abbott (NYSE: ABT) announced today that the HeartMate 3™ Left Ventricular Assist Device (LVAD) has received U.S. Food and Drug Administration (FDA) approval as a destination therapy for people living with advanced heart failure. With the approval, physicians […]
New Long-Term Data Show Improved Survival and Lower Rates of Stroke and Pump Thrombosis for Abbott’s HeartMate 3 Heart Pump
ORLANDO, Fla., March 11, 2018 /PRNewswire/ — Abbott (NYSE: ABT) announced new late-breaking clinical trial data from the MOMENTUM 3 clinical study, the largest left ventricular assist device (LVAD) trial in the world to evaluate patients in need of both short-term and long-term […]
Recent
New Data Demonstrates Vektor Medical’s AI-Powered vMap Algorithm Achieves 91% Accuracy in Distinguishing Epicardial and Endocardial Ventricular Tachycardia, Markedly Surpassing Visual ECG Analysis
Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025
Genomadix Inc. Enters into Collaboration with Mayo Clinic on Precision Medicine for Telestroke
Popular
- No commented posts yet